COVID-19 infection during blinatumomab therapy: Is safety a dilemma?

Julián E. Barahona-Correa; Camilo Rueda-Ortiz; María José López; Sandra Gualtero; Mónica Arevalo-Zambrano

doi:10.1177/2050313X221148548

COVID-19 infection during blinatumomab therapy: Is safety a dilemma?

Julián E. Barahona-Correa
, Camilo Rueda-Ortiz
, María José López
, Sandra Gualtero
, Mónica Arevalo-Zambrano

Hospital Universitario San Ignacio

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient with relapsed acute lymphoblastic leukemia who became positive for SARS-CoV-2 during blinatumomab therapy. There are no formal recommendations on the decision to continue, withhold, or delay blinatumomab treatment in these patients. More studies exploring this issue are warranted, as SARS-CoV-2 is expected to be here to stay.

Original language	English
Journal	SAGE Open Medical Case Reports
Volume	11
DOIs	https://doi.org/10.1177/2050313X221148548
State	Published - 01 Jan 2023
Externally published	Yes

Keywords

Blinatumomab
COVID-19
SARS-CoV-2
precursor cell lymphoblastic leukemia-lymphoma

Access to Document

10.1177/2050313X221148548

Cite this

@article{cd1fd79e344146cfb3e1d0d6bad85ddf,

title = "COVID-19 infection during blinatumomab therapy: Is safety a dilemma?",

abstract = "Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient with relapsed acute lymphoblastic leukemia who became positive for SARS-CoV-2 during blinatumomab therapy. There are no formal recommendations on the decision to continue, withhold, or delay blinatumomab treatment in these patients. More studies exploring this issue are warranted, as SARS-CoV-2 is expected to be here to stay.",

keywords = "Blinatumomab, COVID-19, SARS-CoV-2, precursor cell lymphoblastic leukemia-lymphoma",

author = "Barahona-Correa, \{Juli{\'a}n E.\} and Camilo Rueda-Ortiz and L{\'o}pez, \{Mar{\'i}a Jos{\'e}\} and Sandra Gualtero and M{\'o}nica Arevalo-Zambrano",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2023.",

year = "2023",

month = jan,

day = "1",

doi = "10.1177/2050313X221148548",

language = "English",

volume = "11",

journal = "SAGE Open Medical Case Reports",

issn = "2050-313X",

publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - COVID-19 infection during blinatumomab therapy

T2 - Is safety a dilemma?

AU - Barahona-Correa, Julián E.

AU - Rueda-Ortiz, Camilo

AU - López, María José

AU - Gualtero, Sandra

AU - Arevalo-Zambrano, Mónica

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient with relapsed acute lymphoblastic leukemia who became positive for SARS-CoV-2 during blinatumomab therapy. There are no formal recommendations on the decision to continue, withhold, or delay blinatumomab treatment in these patients. More studies exploring this issue are warranted, as SARS-CoV-2 is expected to be here to stay.

AB - Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient with relapsed acute lymphoblastic leukemia who became positive for SARS-CoV-2 during blinatumomab therapy. There are no formal recommendations on the decision to continue, withhold, or delay blinatumomab treatment in these patients. More studies exploring this issue are warranted, as SARS-CoV-2 is expected to be here to stay.

KW - Blinatumomab

KW - COVID-19

KW - SARS-CoV-2

KW - precursor cell lymphoblastic leukemia-lymphoma

UR - https://www.scopus.com/pages/publications/85146318624

U2 - 10.1177/2050313X221148548

DO - 10.1177/2050313X221148548

M3 - Article

AN - SCOPUS:85146318624

SN - 2050-313X

VL - 11

JO - SAGE Open Medical Case Reports

JF - SAGE Open Medical Case Reports

ER -

COVID-19 infection during blinatumomab therapy: Is safety a dilemma?

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this